Spasticity – Spa Mouse Model
Study novel interventions to improve physical performance in patients affected by muscular Spasticity using the Spa mouse model
Spa Mouse Model Key Characteristics
Spasticity refers to stiff or rigid skeletal muscle tone which affects skeletal muscle contraction, movement, speech, and other daily activities. Spasticity is a symptom that is present in several diseases that affect the neuromuscular system, namely Cerebral palsy, and Amyotrophic Lateral Sclerosis (ALS). Furthermore, spasticity can also arise due to trauma, such as spinal cord injury (SCI) or stroke.Â
As such, spasticity can be modeled using InnoSer’s Spa mouse model which is characterized by a spontaneous spasticity-associated mutation, resulting in early-onset hypertonia. The Spa mouse presents symptoms of spasticity at 2 weeks of age and can reach adult age, making this mouse model highly suitable for therapies aimed at improving skeletal muscle function across multiple conditions or diseases.Â
✓ Spa mice have a hereditary spastic mutation (B6.Cg-Glrbspa/J).
✓ Spastic mice display a series of abnormalities, such, including abnormal gait, impaired hind limb motor function, and reduced physical activity.
✓ Spa mice show skeletal muscle morphology alterations (i.e., muscle mass decrease along with a decrease in the cross-sectional area of myofibers).
✓ Model is extensively characterized (published together with Rivares et al, 2020).
Take advantage of InnoSer’s expertise in modelling neuromuscular disease pathology, flexibility and collaborative approach for your research. Our in-house neurology experts are happy to help guide your decision on study design fit for your current research goals.Â
InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types.Â
Your Neurology Research Starts Here.
Choose the Right Model for Your Research with Confidence
Spa Mouse Model Sample Data
CatWalk Automated Gait Analysis: Gait and footprint analysis of Spa mice
At all ages, the gait of spastic mice was characterized by shorter stride lengths, smaller print- length, and width (P<0.001) together with a lower contact intensity (P<0.01). Spastic mice showed an irregular order of front and hind-limb placements (P<0.001).Â
Spa Mouse Model Readouts
Our Team’s Featured Publications
- Rivares, C., Vignaud, A., Noort, W., Koopmans, B., Loos, M., Kalinichev, M., & Jaspers, R. T. (2022). Glycine receptor subunit-β-deficiency in a mouse model of spasticity results in attenuated physical performance, growth, and muscle strength. American journal of physiology. Regulatory, integrative and comparative physiology, 322(5), R368–R388. https://doi.org/10.1152/ajpregu.00242.2020
- Rivares, C., Vignaud, A., Noort, W., Baan, G., Koopmans, B., Loos, M., Wüst, R. C. I., Kalinichev, M., & Jaspers, R. T. (2024). Muscle type-specific effects of bilateral abobotulinumtoxinA injection on muscle growth and contractile function in spastic mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 38(22), e70141. https://doi.org/10.1096/fj.202302258R
The People Behind Your Research
Thomas Vogels, PhD, In Vivo Neurology Study Director
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
Discover Other Relevant Disease Models
Discover InnoSer’s Latest Research
MDX Mouse Model Validation Data
This month we’re highlighting one of the most commonly used mouse models to study Duchenne Muscular Dystrophy (DMD) – the MDX mouse model B10.mdx), and explore how our advanced services can support your efficacy studies in DMD.  The X-linked muscular dystrophy (MDX)...
InnoSer Announces Joint Initiative with Hasselt University/BIOMED to Support Preclinical Multiple Sclerosis Research
Researchers will benefit from InnoSer’s preclinical drug development expertise combined with Hasselt University’s foundational knowledge in Multiple Sclerosis (MS) to advance preclinical MS research. Diepenbeek, Belgium, ​​October 16th, 2024 — InnoSer, a leading...
Introduction to InnoSer’s Preclinical Epilepsy Research CRO PlatformÂ
Preclinical epilepsy-related research with InnoSer  Broadly speaking, epilepsy is a large spectrum of distinct epileptic syndromes that differ in their etiologies, mechanisms, pathophysiological processes, associated comorbidities, and response profile to available...
Phenotyping of a C3-PMP22 mouse model of CMT1AÂ
Charcot-Marie Tooth (CMT) disease is a hereditary, demyelinating peripheral neuropathy, leading to progressive muscle atrophy, weakness and subsequent walking disabilities and sensory impairments. Charcot-Marie Tooth Type 1A (CMT1A) is the most common type of CMT,...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com